MAP2K1 and glioblastoma: When it activates NRAS/mitogen-activated protein kinase kinase 1(MEK1)/extracellular signal-regulated kinase 1 and 2 (ERK1–2) signals by sponging miR-502-5p, GBM progression and temozolomide resistance is ultimately facilitated (Wei et al. 2021).